Program - KSMO Conference

Scientific Program

September 3 (Wed)
September 4 (THU)
September 5 (FRI)

To Be Updated

Sep. 7 (Thu)

ASCO/KSMO Joint Symposium 1 (JS01)

Targeting rare genomic aberrations in precision oncology

Date & Time	September 7 (Thu), 08:40-10:10	Venue	Room A
Chairs	Everett E. Vokes (The University of Chicago Medicine, USA) Joong Bae Ahn (Yonsei Cancer Center, Republic of Korea)
Session Details	1.Targeting NTRK fusion Lori J. Wirth (Massachusetts General Hospital, USA) 2. Clinical implication of BRAF aberrations in solid tumor Miso Kim (Seoul National University Hospital, Republic of Korea) 3.Ancestry-specific differences in TMB Amin Nassar (Yale University, USA) 4.RAS/RAF aberrations in refractory cancer: What is next? Hee Kyung Kim (Chungbuk National University Hospital, Republic of Korea)

Satellite Symposium 1 (SL01)

Date & Time	September 7 (Thu), 08:40-09:20	Venue	Room B
Chair	TBD
Session Details	TBD

Satellite Symposium 2 (SL02)

Date & Time	September 7 (Thu), 09:30-10:10	Venue	Room B
Chair	TBD
Session Details	TBD

Scientific Symposium 1 (SS01)

T cells need our help to fight cancer, beyond PD-1/PD-L1 inhibitors

The use of T cells in cancer immunotherapy has become a potent weapon in the fight against cancer. While Immune checkpoint inhibitors like PD-1/PD-L1 inhibitors have revolutionized cancer treatment, primary and acquired resistance continue to pose significant challenges. To overcome these limitations, Innovative forms of immunotherapy, such as adoptive T cell transfer and T cell redirection therapy, are now being researched actively. During this session, we will discuss these exciting advances in cancer immunotherapy and their potential to enhance treatment outcomes.

Date & Time	September 7 (Thu), 08:40-10:10	Venue	Room C
Chairs	TBD
Session Details	1. Tumor-infiltrating lymphocyte (TIL) therapy, around the corner? Omid Hamid (The Angeles Clinic and Research Institute, USA) 2. HPK1 is a novel target for immune checkpoint inhibition Eui-Cheol Shin (KAIST Graduate School of Medical Science and Engineering, Republic of Kroea) 3. Optimizing T cell-redirecting strategies: A T-cell redirecting antibody Luis Alvarez-Vallina (Cancer Immunotherapy Unit (UNICA), Spain) 4. CAR T cells for solid tumors; advances and barriers Prasad S. Adusumilli (Memorial Sloan Kettering Cancer Center, USA)

Scientific Symposium 2 (SS02)

The next step in the treatment of GU cancers

This genitourinary cancer session deals with "next step" therapy. It consists of the direction of clinical trials and future landscape of clinical practice of new drugs, which are currently being introduced in the treatment of genitourinary cancer, and how to make the best treatment choice in areas where there is not yet full consensus.
First, we will learn and discuss BiTE and CAR T in prostate cancer and ADC in urothelial carcinoma, and next about choosing initial treatments in metastatic hormone-sensitive prostate cancer and advanced renal cell carcinoma.

Date & Time	September 7 (Thu), 08:40-10:10	Venue	Room D
Chairs	TBD
Session Details	1. Bi-specific T cell engager and CAR T in castration resistant prostate cancer: Hope or hype? Mike Groaning (Amgen, USA) 2. Antibody-drug conjugate in urothelial carcinoma: Current status and future perspectives Jonathan Rosenberg (Weill Cornell Medical College, USA) 3. Combination treatment in metastatic castration sensitive prostate cancer: What to combine and how to sequence? Woo Kyun Bae (Chonnam National University Hospital, Republic of Korea) 4. Choice of 1st line treatment of metastatic RCC: Is there biomarker? Jae-lyun Lee (Asan Medical Center, Republic of Korea))

Plenary Lecture 1 (PL01)

Mechanisms of resistance to endocrine therapy in ER+ breast cancer

Professor Carlos L. Arteaga, M.D., is an internationally recognized expert in breast cancer in the areas of oncogenes and breast tumor initiation and progression, targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. He is the Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at the University of Texas Southwestern Medical Center and served as the President of AACR. This plenary lecture will be on resistance to endocrine therapy in breast cancer, with Dr. Arteaga giving his insights in tumor biology and novel therapeutics.

Date & Time	September 7 (Thu), 10:40-11:20	Venue	Room A
Chair	Seock-Ah Im (Seoul National University Hospital, Republic of Korea)
Session Details	Mechanisms of resistance to endocrine therapy in ER+ breast cancer Carlos Arteaga (UT Southwestern Medical Center, USA)

Luncheon Symposium 1 (LS01)

Date & Time	September 7 (Thu), 11:30-12:10	Venue	Room A
Chair	TBD
Session Details	TBD

Luncheon Symposium 2 (LS02)

Date & Time	September 7 (Thu), 11:30-12:10	Venue	Room C
Chair	TBD
Session Details	TBD

Luncheon Symposium 3 (LS03)

Date & Time	September 7 (Thu), 11:30-12:10	Venue	Room E
Chair	TBD
Session Details	TBD

Scientific Symposium 3 (SS03)

Treatment for NSCLC: The earlier, the better?

There have been significant advances in adjuvant and neoadjuvant systemic chemotherapy for lung cancer, incorporating targeted agents and immunotherapy.
These clinical achievements are regarded as a significant opportunity to advance a cure for lung cancer. However, despite the progress, there are still limits in translating clinical trial results into clinical practice. Further deliberation is needed to define more powerful predictive biomarkers before treatment or to develop subsequent treatment strategies when expected responses are not achieved. In this session, we will discuss various clinical scenarios that arise when applying clinical research results to real-world practice.

Date & Time	September 7 (Thu), 12:30-14:00	Venue	Room A
Chairs	TBD
Session Details	1. Neoadjuvant immunotherapy in NSCLC Mark Awad (Dana-Farber Cancer Institute, USA) 2. Adjuvant immunotherapy in NSCLC Benjamin Besse (Gustave Roussy, France) 3. Beyond treatment in recurred patients treated with upfront immunotherapy Hee Kyung Ahn (Gachon University Gil Medical Center, Republic of Korea) 4. Adjuvant EGFR TKI therapy, sooner is better than later, but not always! Dae-ho Lee (Asan Medical Center, Republic of Kroea)

Satellite Symposium 3 (SL03)

Date & Time	September 7 (Thu), 12:30-13:10	Venue	Room B
Chair	TBD
Session Details	TBD

Satellite Symposium 4 (SL04)

Date & Time	September 7 (Thu), 13:20-14:00	Venue	Room B
Chair	TBD
Session Details	TBD

KSP/KSMO Joint Symposium (JS02)

Location matters: How spatial data is driving precision medicine

Date & Time	September 7 (Thu), 12:30-14:00	Venue	Room C
Chairs	TBD
Session Details	1. The spatial transcriptome: TME difference between primary tumor and brain metastasis Alexander Swarbrick (Garvan Institute of Medical Research, UNSW Sydney, Australia) 2. Current and future perspective of spatial transcriptome Jungmin Choi (Korea University College of Medicine, Republic of Korea) 3. The spatial context of tumor microenvironment Minsun Jung (Yonsei University College of Medicine, Republic of Korea) 4. Spatial genomics maps the structure, character and evolution of cancer clones Lucy Yates (Wellcome Sanger Institute, UK)

KCSG/KSMO Joint Symposium (JS03)

The near future of precision medicine - One more step

Date & Time	September 7 (Thu), 12:30-14:00	Venue	Room D
Chairs	TBD
Session Details	1. Spatial transcriptome analysis for cancer biology Woong-Yang Park (Samsung Medical Center, Republic of Korea) 2. The next horizon of precision oncology trials: Review of global research trends Yeon Hee Park (Samsung Medical Center, Republic of Korea) 3. Updates from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Richard L. Schilsky (The University of Chicago, USA) 4. Designing future clinical trials built on the basis of the KOSMOS II study Jee Hyun Kim (Seoul National University Bundang Hospital, Republic of Korea)

Scientific Symposium 4 (SS04)

Advance of perioperative chemotherapy in resectable or potentially resectable GI cancer

A deeper understanding of the molecular biology of cancer along with the introduction and application of new anticancer drugs have improved the efficacy of anticancer therapy in metastatic digestive tract cancer. Recently, clinical trials on applying such effective chemotherapy even in cases where resection is possible have been actively conducted, showing good results. In this session, we will discuss the peri-operative chemotherapy for resectable gastrointestinal cancer.

Date & Time	September 7 (Thu), 14:10-15:40	Venue	Room A
Chairs	TBD
Session Details	1. Application of perioperative chemotherapy for localized gastric cancer or gastroesophageal junction adenocarcinoma in Asian patients Sun Young Rha (Yonsei Cancer Center, Republic of Korea) 2. Perioperative chemotherapy in resectable or borderline resectable pancreatic cancer Jin-Young Jang (Seoul National University Hospital, Republic of Korea) 3. Total neoadjuvant treatment in rectal cancer Thierry Conroy (University of Lorraine, France) 4. Approach for resectable GI cancer with MSI-H Myriam Chalabi (Netherlands Cancer Institute, Netherlands)

Oral Presentation 1 (OP01)

Date & Time	September 7 (Thu), 14:10-15:10	Venue	Room B
Chairs	TBD
Session Details	TBD

KOSRO/KSMO Joint Symposium (JS04)

Advances in non-operative, organ-preserving strategy

Date & Time	September 7 (Thu), 14:10-15:40	Venue	Room C
Chairs	TBD
Session Details	1. Non-operative management of rectal cancer William A. Hall (Medical College of Wisconsin, USA) 2. Multi-modality therapy to achieve intact-bladder survival Se Hoon Park (Samsung Medical Center, Republic of Korea) 3. Multidisciplinary less invasive approach for head and neck cancer Tomoya Yokota (Shizuoka Cancer Center, Japan) 4. Implication of immune cell (lymphocyte) dynamics during and after chemoradiotherapy in lung cancer patients undergoing maintenance immunotherapy Kyung Hwan Kim (Yonsei Cancer Center, Republic of Korea)

Scientific Symposium 5 (SS05)

Advances in genomics technology and its clinical adaptation

The goal of this session is to showcase the latest advances in genomics technology and their clinical applications, fostering a deeper understanding of their potential in shaping the future of personalized medicine. Our expert speakers will discuss the innovative EPIC-seq technique for inferring epigenetic expression from cell-free DNA analysis, the integration of cell-free RNA in cancer studies, the use of whole-genome sequencing in clinical cancer diagnosis, and a data-centric approach that leverages genomic and transcriptomic data to accelerate cancer drug discovery. Join us to explore the transformative potential of precision medicine in cancer.

Date & Time	September 7 (Thu), 14:10-15:40	Venue	Room D
Chairs	TBD
Session Details	1. Circulating tumor DNA analysis for detection and molecular characterization of cancers Maximilian Diehn (Stanford University, USA) 2. Whole-genome sequencing for clinical diagnosis of cancer Young Seok Ju (KAIST Graduate School of Medical Science and Engineering / Genome Insight Inc., Republic of Korea) 3. Single-cell RNA sequencing in analyzing molecular and cellular dynamics in lung cancer Hae-Ock Lee (College of Medicine, The Catholic University of Korea, Republic of Korea) 4. Genomic and transcriptomic data-centric approach to accelerate cancer drug discovery Abhishek Jha (Elucidata, USA)

Plenary Lecture 2 (PL02)

Genomic diversity and molecular mechanisms driving cancer evolution

Professor Charles Swanton, FRCP BSc PhD, is a clinician scientist whose work is focused on understanding the challenges inherent in managing metastatic cancers and their drug-resistant and incurable nature. He is the Chief Investigator of the TRACERx clinical study which deciphers lung cancer evolution, and his work has led to insights in genomic diversity within cancers (intratumor heterogeneity) and molecular mechanisms driving cancer branched evolution.

Date & Time	September 7 (Thu), 15:50-16:30	Venue	Room A
Chair	Tae Won Kim (Asan Medical Center, Republic of Korea)
Session Details	Genomic diversity and molecular mechanisms driving cancer evolution Charles Swanton (Francis Crick Institute, UK)

ESMO/KSMO Joint Symposium 1 (JS05)

Multiomics approach for precision medicine

Date & Time	September 7 (Thu), 16:30-18:00	Venue	Room A
Chairs	Andrés Cervantes (University of Valencia, Spain) Kyung Hee Lee (Yeungnam University Medical Center, Republic of Korea)
Session Details	1. Biomarkers for precision medicine for targeted agents Benedikt Westphalen (University of Munich, Germany) 2. Predictive factors for immunotherapy Rodrigo Dienstmann (Vall d'Hebron Institute of Oncology (VHIO), Spain) 3. TBD Se-Hoon Lee (Samsung Medical Center, Republic of Korea) 4. TBD

Satellite Symposium 5 (SL05)

Date & Time	September 7 (Thu), 16:30-17:10	Venue	Room B
Chair	TBD
Session Details	TBD

Satellite Symposium 6 (SL06)

Date & Time	September 7 (Thu), 17:20-18:00	Venue	Room B
Chair	TBD
Session Details	TBD

Scientific Symposium 6 (SS06)

Artificial intelligence-empowered precision medicine in oncology: Cancer diagnosis, biomarker development, and drug discovery

Artificial intelligence (AI) technology has brought great changes in cancer diagnosis and treatment. A major example of using AI in the diagnostic field includes predicting future cancer risk of individuals from normal mammography images before actual cancer development. By combining analysis of single cell sequencing technology and pathology images, it is possible to analyze what genomic/transcriptomic features each cell has. In the therapeutic area, AI can predict the treatment response of novel anti-cancer agents by analyzing the interaction between cancer cells and the microenvironment on a pathology slide. In addition, predicting and realizing the 3D structure of proteins has led to great innovation in developing new drugs. In this session, experts in this field will share status updates on implementing AI in precision oncology and share their perspectives.

Date & Time	September 7 (Thu), 16:30-18:00	Venue	Room C
Chairs	TBD
Session Details	1. Optimizing risk-based breast cancer screening policies with reinforcement learning Adam Yala (UC Berkeley and UCSF, USA) 2. Development and clinical application of the deep-learning model based on pathology images Jeanne Shen (Stanford University, USA) 3. AI-powered analysis of spatial transcriptomics for drug development and biomarker discovery Kwon Joong Na (Seoul National University Hospital, Republic of Korea) 4. Artificial intelligence-powered oncogenic driver target discovery and novel drug development Chaok Seok (Seoul National University, Republic of Korea)

Scientific Symposium 7 (SS07)

The blueprint for next-generation therapeutics

In this session, we introduce next-generation anticancer therapeutics that are currently being actively developed through phase 1/2 clinical trials. In the first presentation, we will introduce PROTAC inhibitors, which are gaining attention as the next generation of protein degraders in the field of hormonal therapy. In the second presentation, the presenter will review the current status of developing therapeutics for TP53 mutations, which are frequently found in all types of cancer but have lacked effective treatments so far. In the third presentation, we will hear about the development status of ADCs (Antibody-Drug Conjugates) from LegoChem Biosciences, a Korean ADC development company. Lastly, we are interested in hearing about the prospects of developing new HRD targeting agents, including PARP1 selective inhibitors.

Date & Time	September 7 (Thu), 16:30-18:00	Venue	Room D
Chairs	TBD
Session Details	1. The current development status of anti-cancer PROTAC agents Xin Gao (Massachusetts General Hospital, USA) 2. Targeting TP53 mutations using novel strategies Ecaterina Elena Dumbrava (The University of Texas, MD Anderson Cancer Center, USA) 3. New direction for ADC development in cancer therapeutics Chul-Woong Chung (LegoChem Biosciences, Inc., Republic of Korea) 4. Novel HRD targeting agents Elisabetta Leo (Bioscience, Oncology R&D, AstraZeneca, UK)

Sep. 8 (Fri)

Satellite Symposium 7 (SL07)

Date & Time	September 8 (Fri), 08:00-08:40	Venue	Room A
Chair	TBD
Session Details	TBD

Satellite Symposium 8 (SL08)

Date & Time	September 8 (Fri), 08:00-08:40	Venue	Room C
Chair	TBD
Session Details	TBD

Satellite Symposium 9 (SL09)

Date & Time	September 8 (Fri), 08:00-08:40	Venue	Room D
Chair	TBD
Session Details	TBD

Satellite Symposium 10 (SL10)

Date & Time	September 8 (Fri), 08:00-08:40	Venue	Room E
Chair	TBD
Session Details	TBD

Plenary Lecture 3 (PL03)

SCRUM-MONSTAR & CIRCULATE - Japan platform to accelerate precision oncology innovations; achievement and perspective

Dr. Takayuki Yoshino, M.D. PhD, is the Director for the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East (NCCE) in Chiba, Japan. He has a particular interest in chemotherapy for gastrointestinal cancers, especially for colorectal cancer (CRC), where he focuses on various investigational new agents and translational research.
He is leading a nationwide cancer genome screening project to profile cancer-related genomic alterations in advanced solid tumors (SCRUM). In addition, he is studying the gut microbiome in advanced solid tumors by circulating tumor DNA target panel sequencing and sequencing of 16S rRNA from gut microbiome (MONSTAR).

Date & Time	September 8 (Fri), 09:00-09:40	Venue	Room A
Chair	Taeyou Kim (Seoul National University Hospital, Republic of Korea)
Session Details	SCRUM-MONSTAR & CIRCULATE - Japan platform to accelerate precision oncology innovations; achievement and perspective Takayuki Yoshino (The National Cancer Center Hospital East (NCCE) in Chiba, Japan)

ASCO/KSMO Joint Symposium 2 (JS06)

Recent updates in multimodality cancer treatment

Date & Time	September 8 (Fri), 10:00-11:30	Venue	Room A
Chairs	Lori J. Wirth (Massachusetts General Hospital, USA) Ho Yeong Lim (Samsung Medical Center, Republic of Korea)
Session Details	1. TBD Sandra W. Ryeom (Columbia University Irving Medical Center, USA) 2. Recent Advances in combined modality therapy of early-stage lung cancer Everett E. Vokes (The University of Chicago Medicine, USA) 3. Multimodality treatment in HCC in the IO era Jung Yong Hong (Samsung Medical Center, Republic of Korea) 4. TBD

Satellite Symposium 11 (SL11)

Date & Time	September 8 (Fri), 10:00-10:40	Venue	Room B
Chair	TBD
Session Details	TBD

Satellite Symposium 12 (SL12)

Date & Time	September 8 (Fri), 10:50-11:30	Venue	Room B
Chair	TBD
Session Details	TBD

Scientific Symposium 8 (SS08)

Recent strategies in treatment advances for metastatic GI cancers

This session aims to explore the latest developments in treating metastatic gastrointestinal (GI) cancers. Experts will discuss exciting topics such as novel treatment approaches for advanced gastric cancer, pancreatic cancer, and hepatocellular carcinoma, as well as tissue-agnostic targeted treatments. Attendees can expect to learn about the most promising strategies and their potential benefits for patients with metastatic GI cancers, gaining insight into innovative treatment approaches shaping the future of metastatic GI cancer care.

Date & Time	September 8 (Fri), 10:00-11:30	Venue	Room C
Chairs	TBD
Session Details	1. Advances in targeted therapies for AGC, beyond HER2 Kohei Shitara (National Cancer Center Hospital East, Japan) 2. Novel approaches in treatments for metastatic pancreatic cancer, beyond chemotherapy Wungki Park (Memorial Sloan Kettering Cancer Center, USA) 3. Later-line treatment strategies for advanced HCC in "immunotherapy as 1st line" era Arndt Vogel (Hannover Medical School, Germany) 4. Tissue agnostic targeted treatment approaches for metastatic GI cancers Zev A. Wainberg (UCLA, USA)

Education Session 1 (ES01)

Basics of precision medicine for medical oncologists: What else should we know beyond NGS?

Undoubtedly, precision medicine has unleashed a totally new era of medical oncology conferring an obvious therapeutic benefit for our patients. Although we as medical oncologists are becoming more familiar with NGS in our daily practice, it’s time to expand our comprehension of precision medicine beyond NGS. Accordingly,
this session will review, discuss, and offer insight on timely issues of precision medicine other than NGS. After summarizing the current status of cancer genomics, the concept and application of proteomics and liquid biopsy will be introduced. Interestingly, the ways that AI and precision medicine are converging will also be shared.

Date & Time	September 8 (Fri), 10:00-11:20	Venue	Room E
Chairs	TBD
Session Details	1. Current status and challenges of cancer genomics: NGS and beyond In Hae Park (Korea University Guro Hospital, Republic of Korea) 2. Single RNA sequencing and proteomics: How can we implement them in our research and practice? Han Sang Kim (Severance Hospital, Republic of Korea) 3. The role of AI in the era of precision medicine: When AI meets cancer genomics Chan-Young Ock (Lunit Inc., Republic of Korea) 4. Liquid biopsy in our clinics: Can it be another breakthrough in genomics-driven oncology Sun-Young Kong (National Cancer Center, Republic of Korea)

Luncheon Symposium 4 (LS04)

Date & Time	September 8 (Fri), 11:40-12:20	Venue	Room A
Chair	TBD
Session Details	TBD

Luncheon Symposium 5 (LS05)

Date & Time	September 8 (Fri), 11:40-12:20	Venue	Room C
Chair	TBD
Session Details	TBD

Luncheon Symposium 6 (LS06)

Date & Time	September 8 (Fri), 11:40-12:20	Venue	Room D
Chair	TBD
Session Details	TBD

Scientific Symposium (SS09)

Recent advances in breast cancer treatment

This scientific symposium will cover recent advances in breast cancer treatment, including the development of therapeutic agents and their successful application in clinical settings. The development of CDK 4/6 inhibitors has completely changed the treatment paradigm in hormone receptor-positive breast cancer, and the most promising drug currently receiving attention is oral SERD. Immunotherapy has become the standard of care for triple-negative breast cancer. Novel treatment strategies beyond immunotherapy will be discussed. The discussion will also cover the current and future development of antibody-drug conjugates, such as T-DXd and Sacituzumab govitecan, and the potential need to redefine breast cancer subtypes based on their response to these agents.

Date & Time	September 8 (Fri), 12:40-14:10	Venue	Room A
Chairs	TBD
Session Details	1. The role of oral SERD in ER+ breast cancer Soo Chin Lee (Cancer Science Institute of Singapore, National University of Singapore (NUS), Singapore) 2. State of the art and future directions of antibody-drug conjugates (ADCs) in breast cancer Barbara Pistilli (Gustave Roussy, France) 3. Novel treatments for metastatic triple-negative breast cancer: Beyond immunotherapy Andrei Goga (University of California San Francisco, USA) 4. Should breast cancer subtype be re-established? Kyong-hwa Park (Korea University Anam Hospital, Republic of Korea)

JSMO/KSMO Joint Symposium (JS07)

Emerging immuno-oncology strategy in solid tumors

Date & Time	September 8 (Fri), 12:40-14:10	Venue	Room C
Chairs	Shigehisa Kitano (Cancer Institute Hospital of JFCR, Japan) Myung Ah Lee (The Catholic University of Korea Seoul St. Mary’s Hospital, Republic of Korea)
Session Details	1. Anti-cancer cell therapy in solid tumors Yasutoshi Kuboki (National Cancer Center Japan, Japan) 2. Combination of immune checkpoint inhibitors in solid tumors Shigehisa Kitano (Cancer Institute Hospital of JFCR, Japan) 3. Combination of ICI and targeted agent in solid tumors Moon Ki Choi (National Cancer Center, Republic of Korea) 4. Combination of ICI and cytotoxic chemotherapy in solid tumors In-Ho Kim (The Catholic University of Korea Seoul St. Mary's Hospital, Republic of Korea)

Education Session 2 (ES02)

Practical points in conducting clinical trials

With the development of anticancer drugs using various mechanisms, many kinds of clinical trials have been conducted in which numerous patients have been registered. There can be significant hurdles to conducting clinical trials, including understanding tests and handling adverse events. In this session, we would like to share professional experience and enhance knowledge on the practical points of clinical trials.

Date & Time	September 8 (Fri), 12:40-14:10	Venue	Room E
Chairs	TBD
Session Details	1. Understanding pathology tests from immunohistochemistry to NGS Hyojin Kim (Seoul National University Bundang Hospital, Republic of Korea) 2. Prevention of chemotherapy-induced nausea and vomiting In Hee Lee (Kyungpook National University Chillgok Hospital, Republic of Korea) 3. Management of adverse events associated with tyrosine kinase inhibitors Yun-Gyoo Lee (Kangbuk Samsung Hospital, Republic of Korea) 4. Diagnosis and management of immune-related adverse events Jae Joon Kim (Pusan National University Yangsan Hospital, Republic of Korea)

Plenary Lecture 4 (PL04)

The past & future journey of cancer immunotherapy

Professor Roy S. Herbst, MD, PhD, is a highly respected clinician scientist who has championed novel therapies and research linking genetic abnormalities of cancer cells for lung cancer treatment. He revolutionized the field by introducing diverse molecular targeted therapies and immune checkpoint inhibitors.
His work on "umbrella” trials has galvanized the field of targeted therapy and he led BATTLE-1, BATTLE-2 and Lung-MAP. In his lifetime of achieving scientific contributions in thoracic cancer research, he has made significant advances for the benefit of patients with cancer.

Date & Time	September 8 (Fri), 14:20-15:00	Venue	Room A
Chair	Jin Hyuk Choi (Ajou University Hospital, Republic of Korea)
Session Details	The past & future journey of cancer immunotherapy (tentative) Roy S. Herbst (Yale School of Medicine, USA)

KSR/KSMO Joint Symposium (JS08)

Integrating interventional techniques in the immunotherapy landscape: Novel insights from radiology and oncology

Date & Time	September 8 (Fri), 15:00-16:00	Venue	Room A
Chairs	TBD
Session Details	1. Radioembolization for liver metastasis and cholangiocarcinoma: Hot air or hot stuff Hyo-Cheol Kim (Seoul National University Hospital, Republic of Korea) 2. Radiology perspective: Combining image-guided ablation for enhanced cancer treatment Hyun Pyo Hong (Kangbuk Samsung Hospital, Republic of Korea) 3. Immunotherapy in hepatocellular carcinoma Hong Jae Chon (Cha University Bundang Medical Center, Republic of Korea)

Oral Presentation 2 (OP02)

Date & Time	September 8 (Fri), 15:00-16:00	Venue	Room B
Chairs	TBD
Session Details	TBD

Multi-Disciplinary Case Discussion (MDCD)

Multidisciplinary approach for patients with oligo-metastasis in the era of precision medicine

The role of the oncology multidisciplinary team has become a key component in the care management pathway, helping to ensure that increasingly complex treatment strategies now available are appropriately selected and combined for each individual patient. In this session, we discuss management options for oligometastatic cancer, including an overview of surgical concepts, the current literature on local ablative techniques including stereotactic ablative radiotherapy (SABR), and systemic therapy as an adjunct to local treatment strategies.

Date & Time	September 8 (Fri), 15:00-16:00	Venue	Room C
Chairs	In Hae Park (Korea University Guro Hospital, Republic of Korea) Sun Young Rha (Yonsei Cancer Center, Republic of Korea)
Session Details	Part 1. Practical management in oligometastatic breast cancer?: When, Who, How Min Hwan Kim (Yonsei Cancer Center, Republic of Korea) [Panel Discussion] Hyeong-Gon Moon (Seoul National University Hospital, Republic of Korea) Kyubo Kim (Ewha Womans University Mokdong Hospital, Republic of Korea) In Hae Park (Korea University Guro Hospital, Republic of Korea) Part 2. How to treat oligometastatic gastric cancer? Jin Won Kim (Seoul National University Bundang Hospital, Republic of Korea) [Panel Discussion] In-seob Lee (Asan Medical Center, Republic of Korea) Jeong Il Yu (Samsung Medical Center, Republic of Korea) Sun Young Rha (Yonsei Cancer Center, Republic of Korea)

Education Session 3 (ES03)

ABCs of novel therapeutics for solid cancers: What should we know?

The various challenges undertaken to improve survival rates in oncology are paying off. As new radiation therapy and various ADCs in the field of targeted therapy are being developed, the expectations for new treatments are increasing. In addition, new research results are being reported in oncolytic viruses that have been studied and developed for a long time. This education session will cover the latest insights on proton and carbon therapy, ADCs, and oncolytic virus therapy for researchers entering the changing field of oncology and looking for advanced treatments in addition to those now existing.

Date & Time	September 8 (Fri), 15:00-16:30	Venue	Room E
Chairs	TBD
Session Details	1. 97 Proton therapy and carbon ion therapy for solid cancers Yang-Gun Suh (National Cancer Center, Republic of Korea) 2. Antibody-drug conjugate for targeted cancer treatment Kwang Suk Lim (Kangwon National University, Republic of Korea) 3. Oncolytic virus therapy for cancer Kimun Kwon (Inno.N, Republic of Korea)

FACO Session 1 (FACO01)

Recent updates in colorectal cancer treatment

Date & Time	September 8 (Fri), 15:00-16:00	Venue	Room E
Chairs	Jin Li (FACO Chairman, China) TBD (Republic of Korea)
Session Details	1. TBD 2. Does checkpoint inhibitor work in microstallite stable mCRC patients? Ying Yuan (The Second Affiliated Hospital Zhejiang University School of Medicine, China) 3. Beyond the scalpel: Advancing colorectal cancer management through ctDNA liquid biopsy in the perioperative setting Eiji Oki (Kyushu University, Japan)

ESMO/KSMO Joint Symposium 2 (JS09)

Immunooncology: Holistic perspectives for oncologists

Date & Time	September 8 (Fri), 16:10-17:40	Venue	Room A
Chairs	Benedikt Westphalen (University of Munich, Germany) Kyung Hae Jung (Asan Medical Center, Republic of Korea)
Session Details	1. Molecular tissue imaging to predict response to immunotherapy Jo Van Ginderachter (Vrije Universiteit Brussel, Belgium) 2. Microbiota and nutrition to enhance immunotherapy treatment outcome Lisa Derosa (Institut Gustave Roussy, France) 3. Patient status and response to immunotherapy: From bed to benchside Hye Ryun Kim (Severance Hospital, Republic of Korea) 4. Moving beyond T cells in the tumor microenvironment for next-generation treatment Minsuk Kwon (Ajou University Hospital, Republic of Korea)

Satellite Symposium 13 (SL13)

Date & Time	September 8 (Fri), 10:00-11:30	Venue	Room B
Chair	TBD
Session Details	TBD

Satellite Symposium 14 (SL14)

Date & Time	September 8 (Fri), 10:00-11:30	Venue	Room B
Chair	TBD
Session Details	TBD

KSSO/KSMO Joint Symposium (JS10)

Hereditary cancer - Diagnosis & proper management

Date & Time	September 8 (Fri), 16:10-17:40	Venue	Room C
Chairs	TBD
Session Details	1. Testing criteria of hereditary cancer and clinical application Kyung-Hun Lee (Seoul National University Hospital, Republic of Korea) 2. How to prevent hereditary cancer other than surgery Ji Soo Park (Yonsei Cancer Center, Republic of Korea) 3. Risk reducing surgery in hereditary breast cancer Jai Min Ryu (Samsung Medical Center, Republic of Korea) 4. Risk reducing surgery in hereditary colon cancer Ji Won Park (Seoul National University Hospital, Republic of Korea)

FACO Session 2 (FACO02)

Proposals for new FACO clinical trials

Date & Time	September 8 (Fri), 10:00-11:30	Venue	Room E
Chairs	Masahiko Nishiyama (FACO CEO, Japan) TBD (Republic of Korea)
Session Details	1. TBD Sehhoon Park (Samsung Medical Center, Republic of Korea) 2. Clinical trials: From the viewpoint of a gynecologic oncologist Ning Li (Cancer Hospital Chinese Academy of Medical Sciences, China) 3. International trial group networks in gynecologic cancer area Keiichi Fujiwara (Saitama Medical University International Medical Center, Japan)